Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Raw Materials (2016 - 2018)

Anika Therapeutics has reported Raw Materials over the past 8 years, most recently at $13.2 million for Q3 2018.

  • Quarterly Raw Materials rose 68.31% to $13.2 million in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $13.2 million through Sep 2018, up 68.31% year-over-year, with the annual reading at $11.3 million for FY2017, 91.98% up from the prior year.
  • Raw Materials was $13.2 million for Q3 2018 at Anika Therapeutics, up from $12.6 million in the prior quarter.
  • Over five years, Raw Materials peaked at $13.2 million in Q3 2018 and troughed at $4.9 million in Q3 2015.
  • The 5-year median for Raw Materials is $6.3 million (2017), against an average of $7.4 million.
  • Year-over-year, Raw Materials dropped 28.96% in 2015 and then surged 100.13% in 2018.
  • A 5-year view of Raw Materials shows it stood at $6.2 million in 2014, then dropped by 6.2% to $5.8 million in 2015, then grew by 1.8% to $5.9 million in 2016, then soared by 91.98% to $11.3 million in 2017, then increased by 17.22% to $13.2 million in 2018.
  • Per Business Quant, the three most recent readings for ANIK's Raw Materials are $13.2 million (Q3 2018), $12.6 million (Q2 2018), and $10.1 million (Q1 2018).